@article{2645e62acc9842d7a1d9ee587e16fb0f,
title = "Persistence and adherence to rivastigmine in patients with dementia: Results from a noninterventional, retrospective study using the National Health Insurance research database of Taiwan",
abstract = "Introduction: The objective of the study was to assess adherence and persistence of patients treated with rivastigmine versus donepezil. Methods: Persistence was calculated as the time from the first prescription date of rivastigmine/donepezil until discontinuation/medication switch/end of available data, whichever occurred first. Adherence was calculated as proportion of days covered and medication possession ratio. Results: A majority of patients persisted on 4.5 and 6 mg of rivastigmine for 429 and 468 days, respectively, versus 443 and 441 days for patients receiving 5 and 10 mg of donepezil daily, respectively. Patients who initially received 1.5 mg of oral rivastigmine required a shorter time to reach a stable dose compared with those who initiated treatment at a higher dose of rivastigmine. Patients at a stable dose of 4.5 or 6 mg of rivastigmine were observed to persist longer than those at a lower dose of rivastigmine and donepezil. Discussion: Although results indicate significant difference in persistence between rivastigmine and donepezil groups, clinical significance remains undetermined.",
keywords = "Adherence, Donepezil, National Health Insurance Research Database, Persistence, Rivastigmine",
author = "Chang, {Chee Jen} and Chou, {Tse Chih} and Chang, {Chiung Chih} and Chen, {Ta Fu} and Hu, {Chaur Jong} and Fuh, {Jong Ling} and Wenfu Wang and Chen, {Chiung Mei} and Winco Hsu and Huang, {Chin Chang}",
note = "Funding Information: The study was funded by Novartis (Taiwan) Co., Ltd. This study was based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health, and managed by the HWDC. The interpretation and conclusions contained herein do not represent those of the National Health Insurance Administration, Department of Health, or National Health Research Institutes. The authors wish to thank Preetinder Kaur from Novartis Healthcare Pvt. Ltd., Hyderabad, India, for providing medical writing support for development of the manuscript. All authors reviewed the draft and provided critical comments and approved the final submitted version. Publisher Copyright: {\textcopyright} 2018 The Authors",
year = "2019",
month = jan,
day = "1",
doi = "10.1016/j.trci.2018.06.013",
language = "English",
volume = "5",
pages = "46--51",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",
}